If you are feeling bogged down with work, and you aren’t noticing that to-do list getting any shorter, take a break with these five things to read.
New research into improving the genetic decoding of neurodevelopmental disorders promises to help future diagnosis of children with such conditions.
Physicists have discovered a potential, non-invasive biomarker of Alzheimer’s pathology, detecting the disease before the occurrence of its first symptoms.
Scientists have engineered a new way to deliver CRISPR technology inside cells by repairing the mutation that causes Duchenne muscular dystrophy.
The first gene therapy for cancer, approved by the FDA in August, will transform the treatment process, but it will bring both hope and challenges.
A new study has demonstrated how clinical exome sequencing has helped improve treatment for newborns at Texas Children’s Hospital.
Carl Smith sat down with Cofactor Genomics ahead of their appearance at the Festival of Genomics Boston, to find out more about their new Paragon assay.
Researchers claim that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
George Church has co-founded a new startup that aims to develop “designer proteins” targeting a range of disorders.
Cincinnati Children’s Hospital has collaborated with FDNA to enable help to improve their understanding of complex disorders.
How ready are you for a personalised drug advertisement to pop up on your smartphone, tailored specifically to you? It seems its already upon us.
Pfizer has licensed four products to SpringWorks Therapeutics, to increase chances their of being developed with the backing of outside investors.